What is the ticker symbol for 4D Molecular Therapeutics?

4D Molecular Therapeutics trades under the ticker FDMT on NASDAQ.

What sector does 4D Molecular Therapeutics operate in?

4D Molecular Therapeutics is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze FDMT in a portfolio?

PortView shows FDMT's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.

4D Molecular Therapeutics (FDMT) Stock Analysis

NASDAQHealthcareBiotechnology

$14.19-1.11%

1-year price historyRange $6.47 – $16.76

52-week range$14.19

$6.09$16.93

What 4D Molecular Therapeutics does

4D Molecular Therapeutics, Inc. is a clinical-stage gene therapy company that engineers therapeutic agents by leveraging its proprietary adeno-associated virus (AAV) vector technology. The company's developmental efforts are concentrated across a trio of therapeutic fields: ophthalmology (eye conditions), cardiology (heart ailments), and pulmonology (respiratory disorders). Within its active pipeline, three specific product candidates have advanced into clinical trial phases, all currently undergoing Phase 1/2 clinical assessment: 4D-125 is being evaluated for the treatment of X-linked retinitis pigmentosa. 4D-110 targets choroideremia. 4D-310 is focused on addressing Fabry disease. Beyond these, two Investigational New Drug (IND) candidates are in development: 4D-150, aimed at combating wet age-related macular degeneration, and 4D-710, designed to tackle cystic fibrosis lung disease. To advance its mission, 4D Molecular Therapeutics, Inc. actively engages in research and development partnerships with entities such as uniQure, CRF, Roche, and CFF. The firm commenced operations in 2013 and maintains its headquarters in Emeryville, California.

Key metrics

Market cap

$741.80M

P/E (TTM)

-5.52

EPS (TTM)

$-2.57

Beta

2.69

Dividend yield

0.00%

Revenue / share

$1.31

50-day avg

$12.31

200-day avg

$10.04

52-week high

$16.93

52-week low

$6.09

CEO

David H. Kirn

ETFs linked to FDMT

Broad-market and Healthcare sector ETFs an investor holding 4D Molecular Therapeutics is often also exposed to. Open an ETF page to see its actual top holdings.

SPY — SPDR S&P 500 ETF Trust VOO — Vanguard S&P 500 ETF QQQ — Invesco QQQ Trust VTI — Vanguard Total Stock Market ETF

PortView Portfolio Insights

PortView analyzes how FDMT fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Analyze FDMT in PortView →

Similar companies

JNJ — Johnson &LLY — Eli Lilly A — Agilent Technologies ABBV — AbbVie Inc.ABT — Abbott Laboratories ALNY — Alnylam Pharmaceuticals

Frequently asked questions

What is the ticker symbol for 4D Molecular Therapeutics?: 4D Molecular Therapeutics trades under the ticker FDMT on NASDAQ.
Which exchange is FDMT listed on?: FDMT is listed on NASDAQ.
What sector does 4D Molecular Therapeutics operate in?: 4D Molecular Therapeutics is classified in the Healthcare sector (Biotechnology industry).
How can PortView help analyze FDMT in a portfolio?: PortView shows FDMT's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.

The information provided by PortView is for informational and educational purposes only and does not constitute investment advice. Market data may be delayed. Past performance does not guarantee future results.